Abstract:Abstract Objective: To approach the apparent diffusion coefficient(ADC) obtained on diffusion weighted imaging (DWI) in predicting the response of breast cancer to neoadjuvant chemotherapy.Methods: 53 locally advanced breast cancer patients participated in this prospective study on neoadjuvant chemotherapy. All patients were treated with weekly neoadjuvant paclitaxel plus carboplatin for 4 cycles. DWI and ADC value were examined before chemotherapy(the first time point), after the first and the forth cycle of chemotherapy(the second and the third time point). Patients were categorized as high responders if their ADC at the second time point were higher by 2 times the standard deviation than the mean pre-chemotherapy ADC, and otherwise the patients were considered as low responders. Logistic regression was conducted to examine the independent factors predictive of clinical complete response(CR) and pathologic complete response(pCR).Results: CR was documented in 13 patients (24.5%); partial response in 36 patients (67.9%); stable disease in 4 patients (7.5%) and no patient had progressive disease. 11 patients(20.8%) have achieved pCR. There was a strong positive correlation between the percentage changes in ADC value at the third time points and the degree of the tumor reduction. A significant increase in ADC value was observed at the second time point compared with the first time point (1.104±0.117×10-3mm2/s, 1.220±0.158×10-3mm2/s, P<0.001), while the decrease of the longest diameter of the tumors measured by physical examination, ultrasound or MRI or the tumor volumn measured by MRI were not (P>0.05). Logistic regression revealed that percentage changes of ADC value at the second time point were significantly associated with CR(P=0.022, hazard ratio[HR] =1.08, 95% confidence interval[CI]: 1.01∼1.16) and pCR(P=0.022, HR =1.11, 95%CI: 1.02∼1.21). The AUC value of the receiver operating characteristic curve were 0.721(95%CI: 0.512∼0.931, P=0.017) and 0.775(95%CI: 0.598∼0.952, P=0.005) in the two diagnostic tests for CR and pCR, and the sensitivity and specificity were 76.9%, 63.6% and 77.5%, 90.5%, respectively. According to categorizing system described above, 10 patients(18.9%) were considered as high responders and 43 patients(81.1%) low responders. 7 patients(70%) of the high responders have achieved clinical CR and pCR while for the low responders there were only 6 patients(14.0%) and 4 patients (9.3%) proven to have CR and pCR. The difference have both reached statistical significance(P=0.001, P<0.001). Logistic regression confirmed that the categorizing system was independently predictive of CR(P=0.006, HR=42.26, 95%CI: 2.86∼624.08) and pCR(P=0.013, HR=25.19, 95%CI: 2.00∼318.91). Taking this categorizing system as a dignostic test, the sensitivity and specificity were 53.8% and 92.5% for CR and 63.6% and 92.9% for pCR, respectively.Conclusions: The change of ADC value obtained on DWI after the first cycle of neoadjuvant chemotherapy occured prior to the morphologic changes of the tumor and at this time ADC value could to some extent predict the efficacy of neoadjuvant chemotherapy. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4025.

HCT116 colon cancer xenografts: diffusion weighted MR imaging to assess early chemotherapeutic response

Study on the Therapeutic Efficacy of Subcutaneous Colon Cancer Xenograft Tumor with Ultrasound Destruction of VEGFI-carrying Microbubbles

Initial Experience of Correlating Diffusion Spectral Parameters with Histopathologic Indexes in Murine Colorectal Tumor Homografts

Diffusion‐weighted MRI Monitoring of Pancreatic Cancer Response to Radiofrequency Heat‐enhanced Intratumor Chemotherapy

Correlation of Diffusion‐weighted Imaging Data with Apoptotic and Proliferation Indexes in CT26 Colorectal Tumor Homografts in Balb/c Mouse

The correlation between apparent diffusion coefficient of advanced colorectal cancer and response to chemotherapy

Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases.

Chemotherapy Response Evaluation in A Mouse Model of Gastric Cancer Using Intravoxel Incoherent Motion Diffusion-Weighted Mri and Histopathology

Experimental Study on H22 Hepatocarcinoma Transplanted Model in Mice by MR Diffusion Weighted Imaging Combined with Laboratory Examination

Application of apparent diffusion coefficient for predicting response of hepatic metastases to chemotherapy

A Comparative Study in Rectal Carcinoma between Diffusion Weighted MR Imaging and Histopathologic Response with Preoperative Chemoradiotherapy

Role of Apparent Diffusion Coefficients in Assessment of Response to Chemotherapy in Liver Metastasis Patients

Diffusion-Weighted MRI in Predicting the Efficacy of Neoadjuvant Chemotherapy of Breast Cancer.

Value of MR Diffusion Weighted Imaging in Evaluating Therapeutic Effect of Fluorouracil in Rats Transplanted by Hepatocellular Carcinoma Subcutaneously

Intravoxel Incoherent Motion Diffusion-Weighted MR Imaging for Monitoring the Immune Response of Immunogenic Chemotherapy

Assessment of chemotherapy resistance changes in human colorectal cancer xenografts in rats based on MRI histogram features

Quantitative study in apparent diffusion coefficients evaluate the diffusion-weighted MR imaging for clinical follow-up of liver cancer

Early Detection of Therapeutic Response to Hepatic Arterial Infusion Chemotherapy of Liver Metastases from Colorectal Cancer Using Diffusion-Weighted MR Imaging

Diffusion-weighted Magnetic Resonance Imaging for Predicting the Response of Rectal Cancer to Neoadjuvant Concurrent Chemoradiation

H‐Scan Ultrasound Monitoring of Breast Cancer Response to Chemotherapy and Validation with Diffusion‐Weighted Magnetic Resonance Imaging

Effect assessment of sorafenib-treated advanced hepatocellular carcinoma with diffusion magnetic resonance imaging